Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.
Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.
TG Therapeutics’ multiple sclerosis drug Briumvi will be commercialized in Europe by Neuraxpharm. The Germany-based company paid $140 million up front for certain rights to the drug, which received European Commission approval in June.
Frexalimab, a Sanofi drug candidate with roots at Dartmouth’s medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
BeCare Link has developed software that enables the traditional in-person multiple sclerosis assessment to be done remotely on a patient’s own mobile device. The startup was named the winner of MedCity’s recent Pitch Perfect contest.
The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. While U.S. tests are paused, Sanofi said clinical testing in other countries is continuing with additional safety monitoring.
Biogen struck a deal that could bring a digital therapeutic to its multiple sclerosis product portfolio. The drugmaker is partnering with startup MedRhythms in the development of a therapy that combines sensors, software, and music to improve walking problems in multiple sclerosis patients.
By paying $125 million up front for rights to multiple sclerosis drug candidate orelabrutinib, Biogen secures a place among those companies trying to treat the disease by targeting a particular enzyme highly expressed in the central nervous system. But Biogen still has some catching up to do.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Regulatory T cells, or Tregs, have shown promise as a treatment for autoimmune diseases. Abata Therapeutics has raised $95 million in Series A financing for its Treg technology and CEO Samantha Singer said that multiple sclerosis is the startup's first disease target.
A Helius Medical Technologies medical device that stimulates the brain by sending electrical stimulation to the tongue has received FDA clearance for multiple sclerosis patients. The company says its approach could also have applications in other disorders.
The French drugmaker will take full control of SAR442168, a BTK inhibitor developed for multiple sclerosis that it in-licensed from the California biotech company in 2017.
The companies will use a combination of more than seven years of medical record data with five years of prospective data on 5,000 MS patients, including real-world outcomes data and MRI images. Other disease areas to be explored include hematology and rare diseases.
The company announced the approval of Zeposia, which it acquired when it bought Celgene last year. The company said it would delay commercialization as the healthcare system focuses on the pandemic.